Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high dose gestagen therapy: A comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone

Gynecologic Oncology

Volumn 97, Issue 3, 2005, Pages 740-750

  Vereide, Anne Beate ^a   Kaino, Turid ^a   Sager, Georg ^a   Ørbo, Anne ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Apoptosis; Endometrial hyperplasia; Gestagens; Therapy

Indexed keywords

GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; PROTEIN BAX; PROTEIN BCL 2;

ADULT; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRAUTERINE CONTRACEPTIVE DEVICE; LOW DRUG DOSE; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; STROMA CELL;

ADMINISTRATION, ORAL; ADULT; AGED; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BIOPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTRAUTERINE DEVICES; LEVONORGESTREL; MEDROXYPROGESTERONE; MIDDLE AGED; PRECANCEROUS CONDITIONS; PROGESTINS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 20444456570     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.02.030     Document Type: Article

References (33)

1. A.B. Vereide, M. Arnes, B. Straume, J.M. Maltau, and A. Orbo Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone Gynecol. Oncol. 91 2003 526 533
2. C.G. Nilsson, M. Haukkamaa, H. Vierola, and T. Luukkainen Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD Clin. Endocrinol. (Oxford) 17 1982 529 536
3. A. Perino, P. Quartararo, E. Catinella, G. Genova, and E. Cittadini Treatment of endometrial hyperplasia with levonorgestrel releasing intrauterine devices Acta Eur. Fertil. 18 1987 137 140
4. G. Scarselli, C. Tantini, M. Colafranceschi, G.L. Taddei, G. Bargelli, and N. Venturini Levo-norgestrel-nova-T and precancerous lesions of the endometrium Eur. J. Gynaecol. Oncol. 9 1988 284 286
5. G. Rose, and D. Edmonds Levonorgestrel IUS-treatment for endometrial cystic hyperplasia Gynecology 104 1997 614 616 (case reports)
6. D. Gal Hormonal therapy for lesions of the endometrium Semin. Oncol. 13 1986 33 36
7. A. Ferenczy, and M. Gelfand The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia Am. J. Obstet. Gynecol. 160 1989 126 131
8. B. Lindahl, and R. Willen Endometrial hyperplasia. Clinico-pathological considerations of a prospective randomised study after abrasio only or high-dose gestagen treatment. Results of 2 years follow-up of 292 patients Anticancer Res. 11 1991 403 406
9. T.C. Randall, and R.J. Kurman Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40 Obstet. Gynecol. 90 1997 434 440
10. C.A. Amezcua, J.J. Lu, J.C. Felix, F.Z. Stanczyk, and W. Zheng Apoptosis may be an early event of progestin therapy for endometrial hyperplasia Gynecol. Oncol. 79 2000 169 176
11. T. Maruo, J.B. Laoag-Fernandez, P. Pakarinen, H. Murakoshi, I.M. Spitz, and E. Johansson Effects of the levonorgestrel-releasing intrauterine system on proliferation and apoptosis in the endometrium Hum. Reprod. 16 2001 2103 2108
12. T.E. Vaskivuo, F. Stenback, P. Karhumaa, J. Risteli, L. Dunkel, and J.S. Tapanainen Apoptosis and apoptosis-related proteins in human endometrium Mol. Cell. Endocrinol. 165 2000 75 83
13. R.A. Schwartzman, and J.A. Cidlowski Apoptosis: the biochemistry and molecular biology of programmed cell death Endocr. Rev. 14 1993 133 151
14. T.E. Vaskivuo, F. Stenback, and J.S. Tapanainen Apoptosis and apoptosis-related factors Bcl-2, Bax, tumor necrosis factor-alpha, and NF-kappaB in human endometrial hyperplasia and carcinoma Cancer 95 2002 1463 1471
15. H.M. Morsi, M.P. Leers, M. Radespiel-Troger, V. Bjorklund, H.E. Kabarity, and M. Nap Apoptosis, bcl-2 expression, and proliferation in benign and malignant endometrial epithelium: an approach using multiparameter flow cytometry Gynecol. Oncol. 77 2000 11 17
16. G. Peiro, J. Diebold, G.B. Baretton, R. Kimmig, and U. Lohrs Cellular apoptosis susceptibility gene expression in endometrial carcinoma: correlation with Bcl-2, Bax, and caspase-3 expression and outcome Int. J. Gynecol. Pathol. 20 2001 359 367
17. J.P. Baak, J.J. Nauta, E.C. Wisse-Brekelmans, and P.D. Bezemer Architectural and nuclear morphometrical features together are more important prognosticators in endometrial hyperplasias than nuclear morphometrical features alone J. Pathol. 154 1988 335 341
18. A. Orbo, J.P. Baak, I. Kleivan, S. Lysne, P.S. Prytz, and M.A. Broeckaert Computerised morphometrical analysis in endometrial hyperplasia for the prediction of cancer development. A long-term retrospective study from northern Norway J. Clin. Pathol. 53 2000 697 703
19. J.P. Baak, A. Orbo, P.J. van Diest, M. Jiwa, P. de Bruin, and M.A. Broeckaert Prospective multicenter evaluation of the morphometric D-score for prediction of the outcome of endometrial hyperplasias Am. J. Surg. Pathol. 25 2001 930 935
20. G.L. Mutter, J.P. Baak, C.P. Crum, R.M. Richart, A. Ferenczy, and W.C. Faquin Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry J. Pathol. 190 2000 462 469
21. R.J. Kurman, P.F. Kaminski, and H.J. Norris The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients Cancer 56 1985 403 412
22. A. Huang, N.M. Pettigrew, and P.H. Watson Immunohistochemical assay for oestrogen receptors in paraffin wax sections of breast carcinoma using a new monoclonal antibody J. Pathol. 180 1996 223 227
23. Y. Otsuki, O. Misaki, O. Sugimoto, Y. Ito, Y. Tsujimoto, and Y. Akao Cyclic bcl-2 gene expression in human uterine endometrium during menstrual cycle Lancet 344 1994 28 29
24. A. Gompel, J.C. Sabourin, A. Martin, H. Yaneva, J. Audouin, and Y. Decroix Bcl-2 expression in normal endometrium during the menstrual cycle Am. J. Pathol. 144 1994 1195 1202
25. G.S. Henderson, K.A. Brown, S.L. Perkins, T.M. Abbott, and F. Clayton Bcl-2 is down-regulated in atypical endometrial hyperplasia and adenocarcinoma Mod. Path. 9 1996 430 438
26. T. Nakamura, S. Nomura, T. Sakai, and S. Nariya Expression of bcl-2 oncoprotein in gastrointestinal and uterine carcinomas and their premalignant lesions Hum. Pathol. 28 1997 309 315
27. O. Bozdogan, P. Atasoy, S. Erekul, N. Bozdogan, and M. Bayram Apoptosis-related proteins and steroid hormone receptors in normal, hyperplastic, and neoplastic endometrium Int. J. Gynecol. Pathol. 21 2002 375 382
28. C.A. Amezcua, W. Zheng, L.I. Muderspach, and J.C. Felix Down-regulation of bcl-2 is a potential marker of the efficacy of progestin therapy in the treatment of endometrial hyperplasia Gynecol. Oncol. 73 1999 126 136
29. H.O. Critchley, S. Tong, S.T. Cameron, T.A. Drudy, R.W. Kelly, and D.T. Baird Regulation of bcl-2 gene family members in human endometrium by antiprogestin administration in vivo J. Reprod. Fertil. 115 1999 389 395
30. Z.N. Oltvai, C.L. Milliman, and S.J. Korsmeyer Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death Cell 74 1993 609 619
31. D.T. Chao, and S.J. Korsmeyer BCL-2 family: regulators of cell death Annu. Rev. Immunol. 16 1998 395 419
32. P.A. Rogers, F. Lederman, D. Plunkett, and B. Affandi Bcl-2, Fas and caspase 3 expression in endometrium from levonorgestrel implant users with and without breakthrough bleeding Hum. Reprod. 15 Suppl. 3 2000 152 161
33. R.K. Jones, R.F. Searle, J.A. Stewart, S. Turner, and J.N. Bulmer Apoptosis, bcl-2 expression, and proliferative activity in human endometrial stroma and endometrial granulated lymphocytes Biol. Reprod. 58 1998 995 1002